Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
AZN

AstraZeneca PLC

AZNLSEUnited KingdomHealthcareDrug Manufacturers - GeneralFTSE 100

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa,…more

P/E26.65xP/B5.64xROIC14.1%Dividend yield1.7%
£217.78B
Market Cap
EV: £243.76B
MOM2
QUAL10
VAL4
RSK3
AZN
£217.78B
Market Cap · EV £243.76B

AstraZeneca PLC

MOM2
QUAL10
VAL4
RSK3

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa,…more

Latest RNS from AstraZeneca PLC

Analyst consensus: Buy

As of 10 Nov 2026, 24 analysts rate AstraZeneca PLC a Buy, with 79% buy ratings and a mean price target of 15,991p (range 11,947p–20,490p), +15% vs the current price.

Strong buy: 5Buy: 14Hold: 5Sell: 0Strong sell: 0

Full analyst history →

Valuation vs peers

Peer-relative fair value estimate: 5,953p against a current price of 14,040p (-58%), based on EV/EBITDA.

More Healthcare companies